Pharma & Medical Device GEO Case Study: Regulated Content in AI Answers

⚠️ Composite case study — synthesized from public patterns; not a verified single-company case.

TL;DR

FDA-regulated pharma and medical device brands can earn citations in ChatGPT, Perplexity, Gemini, and Google AI Overviews without violating promotional rules. The winning pattern is not aggressive on-domain copy; it is a compliance-aware combination of unbranded disease education, peer-reviewed source seeding, structured product pages, and continuous prompt monitoring. The case study below shows how one brand executed that pattern and what changed in their measured citation share.

The brand and the problem

The subject of this case study is an anonymized, composite specialty pharma brand we will call Cardiovexa — a US-marketed cardiovascular therapy with a single approved indication, an FDA-required boxed warning, and an active EMA marketing authorization. The composite is modeled on patterns we have observed across publicly reported pharma GEO programs and citation studies, including Real Chemistry's HealthGEO program and the komm.passion / Otterly.AI citation analysis of top-grossing pharma products.

In early 2025, Cardiovexa's marketing team had a recognizable problem:

• Branded organic search was healthy, but AI-driven referral traffic was less than 0.5% of organic search — consistent with industry baselines reported in EVERSANA INTOUCH's 2025 Pharma Generative Search Report.
• When the team prompted ChatGPT, Gemini, Perplexity, and Google AI Overviews with the disease-area's top 50 patient and HCP questions, the brand domain appeared in only 4% of citations. Competitor product pages, payer sites, and a handful of patient-advocacy organizations dominated the source list.
• Medical, Legal, and Regulatory (MLR) reviewers were nervous about "optimizing for AI" because most public GEO advice is written for unregulated SaaS brands and ignores 21 CFR 202 and FDA promotional review expectations.

The goal set by the brand lead was deliberately narrow: earn a defensible share of AI citations on unbranded disease-area queries, without changing on-label product copy in ways that would trigger a Form FDA-2253 resubmission cycle for every edit.

Why this matters for pharma and medtech

Generative engines are now an inflection layer between patients, HCPs, and brands. According to PharmaLive's coverage of the 2025 Pharma Generative Search Report, AI-referral traffic to pharma sites is still small but grew 1,083% year over year, and 59% of AI Overview sources on healthcare keywords already rank in the top 20 organic positions. That means three things at once:

1. Traditional SEO authority still feeds AI engines — but it is no longer sufficient on its own.
2. The brands that already rank well organically have a head start in AI citations, which compounds advantage.
3. AI engines weight sources differently. Yext's analysis of 6.8 million citations across Gemini, ChatGPT, and Perplexity showed each model trusts a meaningfully different source mix, so pharma teams cannot optimize for "AI" as a single channel.

Layered on top is the regulatory reality. Under 21 CFR 202.1, any communication about a prescription drug that is promotional must include fair balance, the indication, and risk information. AI engines do not present fair balance for you. The compliance burden — and the legal exposure if AI misrepresents the brand — sits with the manufacturer.

The 9-month playbook

Cardiovexa ran a 9-month program structured around four workstreams. The team tracked outcomes with a prompt-monitoring tool similar to OtterlyAI and HealthGEO, sampling the same 50-prompt set monthly across four engines.

Workstream 1: Source-footprint audit and rebuild

The first step was not on-site at all. The team mapped every source the four AI engines were currently citing for the top 50 disease-area prompts and clustered them into seven buckets:

• Peer-reviewed literature (PubMed, journal sites)
• Clinical-trial registries (ClinicalTrials.gov, EU CTR)
• Regulatory documents (FDA labels, EMA EPARs)
• Patient-advocacy organizations
• Medical news (Medscape, Healio, Fierce Pharma)
• Payer and HTA sites
• Brand and competitor domains

For each cluster, the team identified where Cardiovexa was structurally absent. The biggest gap was peer-reviewed literature: most cited papers came from the competitor's pivotal trial, with limited downstream review articles citing Cardiovexa's pivotal data. Medical Affairs accelerated three Real-World Evidence (RWE) and post-hoc analysis publications already in the pipeline, prioritizing journals indexed by PubMed and known to be heavily cited by ChatGPT and Perplexity.

The team also requested updates to two patient-advocacy disease pages where Cardiovexa was missing from "current treatment options" sections, supplying balanced, label-anchored language and source citations rather than promotional copy.

Workstream 2: Unbranded disease-state hub

The team launched an unbranded cardiovexa-disease-hub.example microsite — corporate-owned but not product-promotional — built around 22 disease-state articles. Each article was a true reference asset: definition, pathophysiology, diagnostic criteria, treatment landscape (named generically), guideline citations, and FAQs. No product names, no efficacy claims, no comparisons.

This structure mirrors Indegene's GEO/AEO/LLMO trinity guidance for pharma: AI engines reward content that is comprehensive, cited, and answer-shaped, and unbranded education is the safest surface to optimize aggressively.

Each article shipped with:

• A MedicalCondition schema block plus Article and FAQPage JSON-LD
• A 2-sentence llm_summary-style opening paragraph
• 3-5 FAQ entries written answer-first
• Citations to PubMed-indexed sources, guidelines (ACC/AHA, ESC), and FDA/EMA documents
• Internal links to a hub index and to sibling articles

MLR review focused on whether the unbranded hub could be construed as off-label promotion or disease-mongering. The team mitigated risk by prohibiting any branded link, footer, or analytics overlap between the hub and the product site, and by adding a standing disclosure that the hub is sponsored by the corporate parent.

Workstream 3: Structured product pages, on label

The product site itself was not rewritten promotionally. Instead, the team made surgical changes that improved AI parseability without changing claims:

• Added Drug schema with nonProprietaryName, mechanismOfAction, clinicalPharmacology, and warning fields populated directly from the approved label.
• Restructured the indication, dosing, and safety sections under H2/H3 headings that match common patient and HCP question phrasing ("Who is [brand] for?", "How is [brand] dosed?", "What are the most serious side effects?").
• Added a stable, machine-readable
  block on every product page so AI engines pulling fragments are more likely to surface ISI alongside efficacy.
• Linked from each product-page section to the corresponding unbranded hub article.

None of these changes altered approved claims, so they cleared MLR as a single bundle rather than per-edit. The team filed updated screenshots under FDA Form 2253 in the standard quarterly cadence.

Workstream 4: Continuous prompt monitoring and MLR feedback loop

The team ran the 50-prompt set against ChatGPT, Gemini, Perplexity, and Google AI Overviews every two weeks. Three signals were tracked:

• Citation share: percentage of responses citing a brand-owned, hub-owned, or partner-amplified source.
• Misrepresentation rate: percentage of responses making a claim about Cardiovexa that was not supported by the approved label.
• Risk-mention rate: percentage of responses that surfaced any boxed-warning content when efficacy was discussed.

Misrepresentations were triaged with MLR. The team did not attempt to "correct" AI engines directly, but used misrepresentation patterns to prioritize new content (a misrepresentation often pointed at a missing FAQ on the unbranded hub) and, in two cases, to file structured feedback through engine-provided publisher channels.

What changed: 9-month outcomes

At month 9, the same 50-prompt benchmark produced a meaningfully different picture. Numbers below are illustrative of the composite case and consistent with publicly reported ranges from HealthGEO and OtterlyAI customer studies; specific deltas will vary by therapeutic area, competitive intensity, and engine.

• Citation share: 4% → 27% across the four engines, with Perplexity highest (34%) and Google AI Overviews lowest (19%).
• Misrepresentation rate: 11% → 3%. Most residual misrepresentations were on Gemini and concentrated on outdated dosing guidance.
• Risk-mention rate: 22% → 58%. The biggest driver was the structured ISI block on the product site, which AI engines began surfacing alongside efficacy excerpts.
• AI-referred sessions to brand and hub domains: up roughly 9x off a small base, still under 5% of organic traffic but tracking the industry's reported 1,083% YoY growth pattern.

The team did not see a corresponding increase in MLR review burden after the initial setup. Once the unbranded hub was operating under a templated review pattern, monthly content velocity increased without per-asset legal escalation.

Lessons for pharma and medtech teams

1. Off-domain authority moves the needle more than on-domain copy. Most early citation gains came from PubMed-indexed publications and patient-advocacy updates, not product-page edits.
2. Unbranded education is the highest-leverage GEO surface in regulated industries. It is the only place where you can write aggressively answer-first content without triggering promotional review on every edit.
3. Structured data is compliance-friendly. Schema markup and stable section IDs change the parseability of approved content, not the claims. MLR generally accepts this as a non-promotional change.
4. Treat AI engines as separate channels. The Yext citation analysis is right: Gemini, ChatGPT, and Perplexity weight sources differently. Prioritize PubMed for ChatGPT/Perplexity, organic SERP authority and structured data for AI Overviews, and Reddit/forum signal for ChatGPT.
5. Monitor misrepresentation, not just visibility. In regulated industries, an inaccurate citation is a bigger risk than a missed one. Build the MLR feedback loop into the program from day one.

Common mistakes to avoid

• Optimizing the product page for AI without label review. Any change that alters claims, comparisons, or risk presentation is an FDA-2253 event.
• Hiding the unbranded hub behind brand UI. If the hub looks promotional, MLR will treat it that way and the GEO advantage collapses.
• Chasing every AI hallucination. Some misrepresentations come from outdated training data and will resolve at the next model update. Triage by reach and risk severity.
• Treating AI traffic as the KPI. AI-referral sessions are still small. Citation share and misrepresentation rate are the leading indicators; traffic follows.
• Skipping medical-news amplification. Medscape, Healio, and Fierce Pharma are heavily cited by AI engines on HCP-facing queries. Earned coverage there compounds.

How to apply this playbook

If you are a brand lead at a pharma or medical device company starting a GEO program, sequence the work in this order:

1. Run a baseline prompt-set audit across at least four AI engines.
2. Map the current citation footprint into the seven source clusters above.
3. Identify your two largest gaps and plan an off-domain content/PR/publication response.
4. Stand up an unbranded disease-state hub with strict MLR templates.
5. Add structured data and stable section IDs to product pages.
6. Establish a biweekly monitoring cadence with citation share, misrepresentation rate, and risk-mention rate as the three KPIs.
7. Loop misrepresentations back into hub content roadmap and quarterly publication planning.

For a deeper dive into individual building blocks, see our companion guides on citation-readiness checklist, structured data for medical content, and healthcare provider GEO under HIPAA.

Related case studies and references

• Case studies hub
• Healthcare provider GEO under HIPAA
• YMYL content and AI citations
• Citation-readiness checklist
• Structured data for medical content

FAQ

Q: Is generative engine optimization compatible with FDA promotional rules?

Yes, when scoped correctly. GEO for a regulated brand should focus on (1) off-domain source authority, (2) unbranded disease-state education, and (3) structured-data improvements to already-approved on-label product pages. Each of those surfaces can be governed under existing MLR processes and 21 CFR 202.1 obligations without a special AI-specific exception.

Q: Should pharma brands try to make AI engines retract or correct misrepresentations?

Usually no, not directly. Most major engines do not offer a fast, brand-controlled correction channel, and chasing every hallucination is a poor use of MLR time. Treat misrepresentations as content-roadmap signal: if AI is wrong on a topic, it is usually because the public web is missing or weak on that topic. Fix the public web (publication, hub article, advocacy page) and the misrepresentation tends to resolve at the next model refresh.

Q: Which AI engines should pharma and medtech teams prioritize?

Prioritize the four engines that drive most healthcare exposure today: ChatGPT, Google AI Overviews, Gemini, and Perplexity. Yext's 6.8M-citation analysis and the komm.passion / Otterly.AI pharma citation study both show meaningfully different source mixes across these engines, so monitor them separately and tune source strategy per engine.

Q: Do medical device brands need a different GEO approach than pharma?

The core playbook is the same: off-domain authority, unbranded education, structured product pages, monitoring loop. The differences are mostly regulatory. Medical device manufacturers operate under FDA CDRH guidance and (for software-as-a-medical-device) the AI-Enabled Medical Device List, which means risk-class and indication-for-use language must be handled with the same care as pharma indication and ISI sections.

Q: How long does it take to see citation-share gains?

In this composite case study, meaningful gains appeared around month 4-5 and compounded through month 9. Realistic expectation for most regulated brands is 6-12 months to move citation share by 10+ percentage points on a defined prompt set, assuming the publication pipeline and MLR process can sustain biweekly content shipping.